Can No­var­tis slim down CAR-T man­u­fac­tur­ing time­lines with its lat­est ac­qui­si­tion at­tempt?

No­var­tis has of­fered to buy a cell and gene ther­a­py man­u­fac­tur­er in an on­go­ing ef­fort to un­clog a com­mer­cial roll­out for its pi­o­neer­ing CAR-T ther­a­py Kym­ri­ah that’s been slowed down by man­u­fac­tur­ing woes.

Set to be­come a whol­ly owned No­var­tis fa­cil­i­ty, Cell­for­Cure first signed an agree­ment to pro­duce Kym­ri­ah in Ju­ly 2018. With the tech trans­fer com­plete, the clin­i­cal sup­ply pro­duc­tion is ex­pect­ed to be­gin by mid-2019 — when the deal is ex­pect­ed to close.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER